Shaperon is a clinical-stage biotech based in Seoul, South Korea, advancing innovative drugs for immune and inflammatory diseases.

Shaperon's main portfolio focuses on novel small molecule GPCR19 agonists. Unlike competitor candidates that failed due to mixed orthosteric-allosteric binding profiles, our molecule utilizes a unique allosteric binding mechanism. This modulation of the GPCR10-P2X7 axis suppresses broad inflammatory cytokines by controlling both priming and activation phases, whereas conventional approaches encompass partial control. We are currently advancing clinical programs in atopic dermatitis, diabetic foot ulcers, Alzheimer's, and IPF.

Our second R&D arm leverages proprietary alpaca-derived NanoMabs (nanobodies). Integrated with high-throughput screening, this platform enables rapid generation (3 months) of stable nanobodies. Our highly versatile NanoMabs support multi-specific formats, advancing novel oncology and viral therapies beyond conventional antibodies.